Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 2 Dose Regimens of Orally Administered SENS-111 (100 mg and 200 mg) Given During 4 Days in Patients Suffering From Acute Unilateral Vestibulopathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Seliforant (Primary)
- Indications Vertigo
- Focus Proof of concept; Therapeutic Use
- Sponsors Sensorion
- 12 May 2020 Status changed from active, no longer recruiting to completed.
- 01 Feb 2020 This trial has been completed in Czech Republic, according to European Clinical Trials Database record. (2019-11-14)
- 20 Dec 2019 This trial has been completed in Germany and Hungary, according to European Clinical Trials Database record.